PPPaula Elena Papuc

Paula Elena Papuc

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paula Elena Papuc has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Patient-Reported Trajectories After Intestinal Stoma Formation: A Prospective Longitudinal Study of Stoma-Related Outcomes and Global Quality of Life

    by Filippo Carannante, Asia Rizzini, Valentina Miacci, Francesca Carnevale, Paula Elena Papuc, Fausto D’Agostino, Gianluca Costa, Gabriella Teresa Capolupo

    Background: Recovery after intestinal stoma formation involves practical, psychological, social, and functional changes that may not evolve in parallel with patients’ overall perception of quality of life. This study examined patient-reported trajectories during the first six postoperative months and explored whether multidimensional stoma-related outcomes followed the same pattern as directly reported global quality of life. Methods: This prospective single-centre observational study included patients with complete assessments at approximately 2 weeks, 1 month, 3 months, and 6 months after ileostomy or colostomy formation. Patient responses were collected at each follow-up and subsequently manually transcribed into an electronic study database. The primary exploratory outcome was a corrected 30-component stoma-related patient-reported composite index (range 0–30; higher values more favourable) derived from an adapted, non-validated questionnaire. A direct 0–10 global quality-of-life item, which also contributed one component to the composite, was analysed separately. Longitudinal change was assessed using Friedman tests with Bonferroni-adjusted Wilcoxon signed-rank comparisons. Post hoc robustness analyses recomputed the composite after excluding the global quality-of-life component and after additionally excluding the sexual-activity components. Results: Our study included 23 patients. The median composite index increased from 9.4 (IQR 7.2–13.6) at 2 weeks to 10.9 (8.7–13.6) at 1 month and 12.2 (9.3–15.3) at 3 months and was 11.8 (9.3–17.2) at 6 months (Friedman chi-square(3) = 19.08, p < 0.001; Kendall’s W = 0.276). Bonferroni-adjusted comparisons were significant for 2 weeks versus 3 months (p = 0.037), 2 weeks versus 6 months (p = 0.016), and 1 month versus 6 months (p = 0.045). Median global quality-of-life ratings were 5, 6, 6, and 5, respectively, with no significant longitudinal change (p = 0.753). Excluding the global quality-of-life component from the composite produced a similar overall result (Friedman chi-square(3) = 19.38, p < 0.001). Conclusions: The exploratory composite showed statistically significant longitudinal change during the first six postoperative months, whereas directly reported global quality of life did not show a parallel change. Because the composite is non-validated and no threshold for clinically meaningful change has been established, these findings should not be interpreted as demonstrating clinically meaningful improvement in adaptation or quality of life. Rather, they suggest that several stoma-related patient-reported dimensions may change over time differently from global quality of life. These findings are exploratory and require confirmation in larger cohorts using validated patient-reported outcome measures.

  • Open Access

    The New Robotic Platform Hugo™ RAS for Colorectal Surgery: A Single-Center Initial Experience

    by Gabriella Teresa Capolupo, Filippo Carannante, Paula Elena Papuc, Valentina Miacci, Martina Marrelli, Francesca Carnevale, Gianluca Bongiorno, Vincenzo Schiavone, Marco Caricato, Gianluca Costa

    Background: Robotic surgery represents the most advanced evolution of minimally invasive colorectal procedures. The Hugo™ Robotic-Assisted Surgery (RAS) platform by Medtronic, introduced in 2021, is a novel modular system designed to enhance accessibility and flexibility. Evidence on its application in colorectal procedures remains limited. This study aimed to evaluate the perioperative outcomes of major colorectal resections performed using the Hugo™ RAS system. Methods: A retrospective, consecutive, single-center case series was conducted on all adult patients who underwent major colorectal surgery using the Hugo™ RAS platform between May 2024 and March 2025. Primary endpoints included operative time, docking time, conversions, and intraoperative complications. Secondary endpoints included postoperative complications (classified using Clavien–Dindo), length of stay, time to bowel function recovery, postoperative pain, and readmission. All perioperative variables were standardized with defined measurement criteria, and complication severity was systematically graded. Results: Forty-four patients were included. All surgeries were completed robotically without conversion or intraoperative complications. The median docking time was 11 min, the median console time was 179 min, and the median operative time was 300 min. Four patients (9.1%) developed major complications (Clavien–Dindo III). Right colectomy anastomoses were intracorporeal, performed with a laparoscopic linear stapler through the assistant port due to absence of a robotic stapler. Conclusions: Major colorectal resections performed with the Hugo™ RAS platform were feasible and safe, with satisfactory perioperative outcomes and no conversions. These findings confirm the reproducibility of this novel robotic system in colorectal surgery. Larger prospective multicenter studies with extended follow-up are warranted to further assess long-term and oncological outcomes.


  • Open Access

    A Focus on Inflammatory and Bacterial Biomarkers in Secondary Peritonitis

    by Valentino Bezzerri, Lorenza Putignani, Elisabetta Mantuano, Alessandro Polini, Luca Navarini, Marta Vomero, Erika Corberi, Valentina Miacci, Paula Elena Papuc, Vincenzo Schiavone, et al.

    Secondary peritonitis is a life-threatening intra-abdominal condition arising from gastrointestinal perforation, chemical injury, or catheter-related infections, characterized by marked heterogeneity in presentation and progression. Major subtypes include stercoraceous peritonitis with fecal contamination, fibrinous peritonitis triggered by bile or gastric contents, peritoneal dialysis-associated infections, and pancreatitis-associated chemical peritonitis. Regardless of etiology, these conditions share profound local and systemic inflammatory responses, contributing to high morbidity and mortality. Biomarkers such as procalcitonin (PCT), interleukin-6 (IL-6), high mobility group box 1 (HMGB1), C-reactive protein (CRP), lipopolysaccharide (LPS), neutrophil-to-lymphocyte ratio (NLR), and neutrophil gelatinase-associated lipocalin (NGAL) have emerged as tools for early diagnosis, subtype stratification, and monitoring of therapeutic response. Their prognostic value is particularly relevant in peritoneal dialysis and postoperative intensive care. Advances in multi-omics, patient-derived organoids, peritoneum-on-chip models, and microbiota profiling are reshaping understanding of peritoneal pathophysiology, revealing cellular heterogeneity, immune-microenvironment interactions, and mechanisms of fibrotic remodeling. Key translational challenges include assessing whether omics-derived signatures can predict the need for early re-laparotomy or the risk of abdominal compartment syndrome. Integration of high-dimensional biomarker profiling with mechanistic and functional studies promises a new era of precision medicine in secondary peritonitis, enabling risk-adapted interventions, complication prevention, and tailored strategies to improve outcomes.